Celldex Therapeutics Finishes 2017 With Plenty of Cash and High Hopes

It's not your standard earnings release when a clinical-stage biotech announces a quarterly update. Usually, financial results aren't nearly as important as pipeline news. That was certainly the case for Celldex Therapeutics (NASDAQ: CLDX) in November, when the company reported its third-quarter results.

And it was the same story on Wednesday, when Celldex announced its fourth-quarter and full-year 2017 results. Although the biotech provided an update on its financial condition, the most important story related to several key pipeline developments. Here are the highlights from the fourth-quarter update.

Celldex results: The raw numbers


Q4 2017

Q4 2016

Year-Over-Year Change


$3.45 million $1.87 million


Net loss

($3.84 million) ($32.31 million)


Net loss per share

($0.03) ($0.30)


What happened with Celldex this quarter?

All of Celldex's revenue at this point in the company's life stems from licensing, contracting, or grants. In the fourth quarter of 2017, the biotech made nearly $2.8 million from contracting and grants, with $665 million coming from product development and licensing agreements. The solid year-over-year increase in total revenue resulted primarily from manufacturing service agreements with the International AIDS Vaccine Initiative and Frontier Biotechnologies, Inc.

This increase in revenue helped Celldex's fourth-quarter bottom line improve to some extent. However, a bigger positive impact came from a one-time tax benefit of $19.1 million recorded in the fourth quarter.

The most important financial metric for Celldex was its cash position. At the end of 2017, cash, cash equivalents and marketable securities totaled $139.4 million, down slightly from $140.5 million as of Sept. 30, 2017. Celldex used $19.5 million for operating expenses in the fourth quarter, but raised an additional $18.4 million in net proceeds from a stock offering.

Celldex highlighted several important pipeline developments made in the fourth quarter or earlier this year. These include:

  • Completed enrollment in the glembatumumab vedotin (glemba) plus checkpoint inhibitor cohort of a phase 2 study targeting treatment of metastatic melanoma. Enrollment has also recently opened in a glemba plus CDX-301 cohort for patients who failed checkpoint therapy.
  • Completed enrollment in January 2018 for a phase 2 study evaluating varlilumab (varli) in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo in treating colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, renal cell carcinoma, and glioblastoma.
  • Kicked off a phase 2 study of CDX-3379 in combination with Eli Lilly's Erbitux in head and neck squamous cell carcinoma.
  • Expanded a phase 1 study of antibody-drug conjugate CDX-014 to include patients with ovarian cancer.
  • Began a phase 1 study of CDX-1140 in treating solid tumors.

What management had to say

Celldex CEO Anthony Marucci looked back at the year that was and what lies ahead:

Looking forward

By far, the biggest thing for Celldex investors to look forward to is the top-line primary endpoint data from the Metric study of glemba in treating triple-negative breast cancer. This data is expected in the second quarter. If results from the study are positive, Celldex plans to work with the U.S. Food and Drug Administration for a potential regulatory filing for glemba in the second half of 2019. It's no exaggeration that 2018 could be the biotech's best year yet if the Metric study is successful.

The phase 2 combo studies with established cancer drugs also are ones to closely watch. Celldex and Bristol-Myers Squibb expect to report preliminary data from the study of varli and Opdivo at medical meetings later in 2018. Results from the study of CDX-3379 and Erbitux, which Celldex is running on its own without assistance from Lilly, could be available by the end of 2019.

10 stocks we like better than Celldex TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celldex Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of March 5, 2018

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Celldex Therapeutics. The Motley Fool has a disclosure policy.